Bacil Pharma share news, announcements and annual reports
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹18.40.
30 Oct: open ₹18.50, high ₹18.99, low ₹18.40
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹27 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 1.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,126
Bacil Pharma share news and announcements
542 announcements, routine notices left out, newest first. Page 3 of 11.
Apr 2025
23 Apr · Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Mar 2025
24 Mar · Announcement under Regulation 30 (LODR)-Allotment
12 Mar · Board meeting
Meeting on 12 Mar 2025: preferential issue of shares12 Mar · Announcement under Regulation 30 (LODR)-Allotment
11 Mar · In-Principle Approval Granted By Stock Exchange
11 Mar · Results
Feb 2025
Jan 2025
21 Jan · Results
21 Jan · Results
13 Jan · Board meeting
Meeting on 21 Jan 2025: quarterly results
Dec 2024
Nov 2024
14 Nov · Meeting
12 Nov · Corrigendum To The Notice Of The EOGM Dated 15/10/2024
Oct 2024
23 Oct · Board meeting
23 Oct · Board meeting
16 Oct · Board meeting
Meeting on 23 Oct 2024: quarterly results15 Oct · Board meeting
15 Oct · Board meeting
15 Oct · Board meeting
10 Oct · Board meeting
Meeting on 15 Oct 2024: preferential issue of shares
Sep 2024
27 Sep · Announcement under Regulation 30 (LODR)-Change in Registered Office Address
27 Sep · Board meeting
27 Sep · Management
27 Sep · Meeting